Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. The company has two FDA-approved products: Revuforj (revumenib), the first and only approved menin inhibitor for the treatment of adult and pediatric patients with relapsed or refractory acute myeloid leukemia (AML) with susceptible NPM1 mutations or KMT2A translocations; and Niktimvo (axatilimab-csfr), a first-in-class CSF-1R-blocking antibody approved for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Niktimvo is co-developed and co-commercialized with Incyte, with Syndax recording 50% of net commercial profit. The company is conducting multiple clinical trials across the acute leukemia treatment continuum, including pivotal Phase 3 trials of revumenib in frontline AML (EVOLVE-2 and REVEAL-ND). Beyond oncology and hematology, axatilimab is being studied in idiopathic pulmonary fibrosis (IPF). Syndax recently expanded its pipeline with SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. The company targets a U.S. total addressable market exceeding $5 billion across relapsed/refractory and frontline acute leukemia settings. Updated Aug 4, 2026